Expertise powering every program.

Jeffrey Adamo is a protein engineering scientist with more than 20 years of experience advancing biologics in the Seattle biotech startup ecosystem, from molecular design through preclinical candidate selection. He combines deep hands-on expertise in protein expression, purification, and in vitro characterization with modern software skills to build data and workflow tools that streamline biologics discovery and development. 

Jeffrey holds a BS in Biochemistry from Western Washington University and a Certificate in Full Stack Web Development from the University of Washington.

David L. Bienvenue, PhD, is a biotechnology leader with deep expertise in protein sciences and therapeutic protein development. Drawing on ~​25 years of industry experience, he has led teams advancing novel biologics from concept through preclinical and early clinical development, with a particular focus on developability. As Senior Director of Protein Sciences at Vedana, he leads a team of scientists dedicated to protein production, candidate evaluation and oversight of related activities at external CROs. Previously, David served as Senior Director of Protein Sciences at Bonum Therapeutics (a spinout of Good Therapeutics that was acquired by Roche).  He spent several years at Aptevo Therapeutics, where he drove bispecific antibody evaluation and formulation and led a cross‑functional Early Product Development Team to translate new mechanisms of action into clinical candidates.  

David holds a BS in Chemistry from Rivier College and PhD in Biochemistry from Utah State University.

Augustine Bourne is a business development executive with more than 15 years of experience in biotechnology and financial services. He most recently served as Head of Business Development at Sapience Therapeutics. Previously, he held business development leadership positions at Mirati Therapeutics and Regeneron, where he led strategic partnering initiatives, managed key alliances, and supported significant corporate transactions, including Mirati’s acquisition by Bristol Myers Squibb. Augustine began his career as a corporate attorney at Weil, Gotshal & Manges in London and New York.

Augustine holds an M.Biochem. from the University of Oxford, a G.D.L./L.P.C. from BPP Law School, and an MBA from Columbia Business School.

Huyen Dinh is a cell-based assay scientist with more than 25 years of experience developing functional and potency assays to support immuno-oncology and inflammation programs. She spent roughly a decade at Amgen building primary human cell assays, and has since led assay work across Seattle immuno-oncology companies including Kineta and OncoResponse. Her expertise spans assay development and validation, in vitro and in vivo pharmacodynamic models, and translational research from target discovery through IND-enabling studies.

Huyen holds a BS in Microbiology and Immunology from University of Washington.

Jit Khim is an in vivo pharmacology scientist with more than 20 years of experience designing and executing animal studies to support therapeutic discovery and development. He spent over a decade in the Rawlings Lab at Seattle Children’s Research Institute leading in vivo immunology studies, and contributed to the IND filing of a lead molecule at Link Immunotherapeutics. His expertise spans in vivo study design, advanced dosing and surgical techniques, IVIS and laser Doppler imaging, and IACUC protocol development.

Jit holds a BS in Zoology from the University of Washington.

Brian Kovacevich is an antibody discovery and development leader with more than 20 years of experience advancing therapeutic antibodies from discovery through IND-enabling studies. He discovered the CGRP antibody at Alder Biopharmaceuticals and has led programs spanning antibody engineering, humanization, and bispecific platforms. His work has brought multiple antibodies into clinical trials, with deep expertise in molecular biology, antibody optimization, and translational development.

Brian holds a BS in Cellular and Molecular Biology from University of Washington, and pursued graduate studies in molecular biology at UC San Diego and University of Washington.

Cristina Moldovan Loomis, PhD is a biopharmaceutical program leader with over 20 years experience in preclinical development of biologics that has delivered multiple therapeutics into clinical development. She currently serves as Director of Pharmacology at Vedana Therapeutics, where she leads pharmacology and preclinical development for mono‑ and multispecific antibody programs supporting first‑in‑human studies. At Alder BioPharmaceuticals, she led the PACAP biology team and provided preclinical support for anti-CGRP antibody eptinezumab, for migraine therapy.  She held leadership positions at Just-Evotec Biologics, Bayer Healthcare and Medarex, where she has guided programs across discovery biology, pharmacology, translational science and IND-enabling studies.

Cristina holds a BS in Microbiology & Immunology and a PhD in Immunology from McGill University. She has completed postdoctoral training at UCSF (University of California San Francisco).

Lisa McCulloch, PhD, is a bioanalytical scientist with more than 15 years of experience in the development of bioanalytical assays and driving bioanalytical programs across the pharmaceutical spectrum from preclinical through clinical stages. She was an integral part of the bioanalytical team at Alder and Lundbeck Biopharmaceuticals, developing all assays for both CGRP and PACAP targeting therapeutics. Her expertise includes development of all pharmacokinetic, anti-drug antibody, neutralizing antibody and potency assays required for regulatory submission as well as design of innovative assays tailored to specific program requirements. Her bioanalytical expertise has advanced multiple drug candidates through IND, clinical trials and approval.

Lisa holds a BA from Mount Holyoke College and a PhD in Biology from The University of Maryland, College Park.

Justin Pinkston, PhD, is a biochemist and protein engineer specializing in monoclonal and multispecific antibody design and analytical characterization. He has developed expertise in complex protein design, expression, purification, and crystallization, most recently advancing antibody programs as a scientist at SystImmune. His technical strengths span biolayer interferometry, chromatography and analytical characterization, and structure-guided protein engineering.

Justin holds a BS in Biochemistry and a PhD in Biochemistry from Utah State University.

Kristie Rollins has decades of experience in biologics and complex modalities, spanning development and regulatory milestones. She has led cross-functional teams through IND, CTA and BLA submissions. She has also established governance and risk management frameworks that drive operational efficiency in fast-paced biotech environments. Her core expertise includes CMC strategy, tech transfer, and vendor/partner management. Kristie began her biologics career in purification process development, providing a strong technical foundation for her leadership. 

She holds a BS from Auburn University and has completed formal training in biotechnology and project management.

Noelle Yaitanes is a protein sciences researcher with experience supporting biologics and therapeutic protein programs across discovery and preclinical research. She has contributed to protein engineering and de novo protein design efforts for research‑use‑only and diagnostic applications in her previous roles in early-stage start-ups.

Originally from California, she received her BS in Biochemistry and Molecular Biology from UC Santa Cruz.